"We believed that it was our mandate to incorporate the best of current knowledge in the areas of prognostic indications, treatment, and supportive care, but with a strong bias that we should not settle for the mediocre outcomes that were the norm at that time." Dr. O'Donnell, who has chaired the NCCN Guidelines Panel for AML since 1996, noted, since the inception of the AML panel, that clinical trials were to be considered as a high priority in initial therapy.
http://ift.tt/1Bq4G4J
http://ift.tt/1Bq4G4J
No comments:
Post a Comment